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Abstract
Background. Patients with chronic kidney disease stage 5
have a high prevalence of vascular calcification, but the
specific anatomical distribution and severity of abdominal
aortic calcification (AAC), in contrast to coronary calci-
fication, is less well documented. AAC may be recorded
using plain radiographs. The present report is an analysis
of baseline data on AAC in patients enrolled in the CORD
(Calcification Outcome in Renal Disease) study.
Methods. A total of 47 centres in six European countries
participated in this cross-sectional study. Inclusion criteria
were age ≥18 years and duration of dialysis ≥3 months.
Laterallumbarradiographyoftheabdominalaortawasused
to determine the overall AAC score, which is related to the
severity of calcific deposits at lumbar vertebral segments
L1–L4. The reliability of the method was tested by double
reading of 64 radiographs (coefficient of correlation 0.9).
Results. A lateral lumbar radiograph was obtained in
933 patients. Calcification (AAC score ≥ 1) was present
in 81% of the patients; its severity increased significantly
f r o mL 1t oL 4( P < 0.0001) and affected all of these seg-
ments in 51% of patients. Independent predictors for the
presence and severity of calcification were age (odds ratio
[OR] 1.103/year; P < 0.0001), duration of dialysis (OR
1.110/year; P = 0.002) and history of cardiovascular dis-
ease (OR 3.247; P < 0.0001).
Conclusions.AACdetectedbylaterallumbarradiographis
associatedwithseveralriskfactorsofuraemiccalcification.
Thissemi-quantitativemethodismorewidelyavailableand
less expensive than the current procedures for studying
calcificationandcouldformpartofapre-transplantworkup
and cardiovascular risk stratification.
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Introduction
Patients with stage 5 chronic kidney disease (CKD) on
dialysis have a greatly increased atherosclerotic burden,
which often progresses over a relatively short period of
time [1,2]. This phenomenon affects even young dialysis
patients [3] and probably explains in part why cardiovas-
cular mortality is increased 20- to 30-fold in this group
compared with an age-matched population [4]. Over the
past few years, numerous studies have elucidated potential
pathogeneticmechanismsleadingtotheacceleratedcalcifi-
cationofbloodvessels(reviewedin[5]).Ithasalsobecome
evident that traditional risk factors for atherosclerosis, such
as dyslipidaemia, hypertension, smoking, gender and age,
only partly explain the calcification that seems to be more
linked to the uraemic milieu and abnormalities in mineral
metabolism [1,6].
Atherosclerosis in the coronary arteries and other vascu-
lar beds correlates with the extent of lesions in the aorta
[7], and several studies have suggested that plain radio-
graphs of pelvic and thigh vessels [8] and thoracic aorta
[9] may be useful methods of assessment. The abdominal
aorta is relatively simple to investigate radiologically, but
no well-standardized method has been used in patients with
end-stage renal disease (ESRD). A system for quantifica-
tionofcalcificationwasdescribedbyKauppilaetal.[10]in
a subgroup of participants of the Framingham heart study.
It relies on lateral lumbar radiographs and the calculation
of the abdominal aortic calcification (AAC) score. This
method was studied initially in 617 subjects and its pre-
dictive value for cardiovascular events and mortality was
validated in a large cohort of 2500 subjects in the Fram-
ingham heart study [11,12]. Recently, the AAC score was
C   The Author [2008].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version
of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed
as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or
as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org4010 E. Honkanen et al.
shown to correlate well with electron beam computer to-
mography (EBCT) scores of coronary arteries in chronic
haemodialysis patients [13]. AAC may also be associated
with all-cause and cardiovascular mortality in ESRD [14].
The Global Bone and Mineral Initiative Working Group
of the Kidney Disease Improving Global Outcomes
(KDIGO) managed by the National Kidney Foundation
recommended screening for the presence of cardiovascu-
lar calcification with simple office-based methods to make
itaccessibletoagreaternumberofnephrologists.Acardio-
vascular calcification index (CCI) has been developed by
Muntner et al. [15] comprising demographic information,
dialysis vintage and simple imaging procedures including
plain lateral lumbar X-ray pulse pressure and an echocar-
diogram. These procedures are widely available, less costly
and have been shown to have an acceptable sensitivity and
specificity. Such testing could form the basis for deter-
mining which patients might benefit from more focused
investigations.
The CORD (Calcification Outcome in Renal Disease)
studyisanepidemiologicalstudyindialysispatients,aimed
toquantifyarterialcalcificationandstiffnessandtoidentify
riskfactorsrelatedtotheseprocesses.Inaddition,thestudy
also evaluates the progression over time and the indepen-
dentpredictivevalueoftheseparametersfortheoccurrence
of cardiovascular events and mortality over a 24 months’
follow-up period. The present report is an analysis of the
baseline data on vascular calcification.
Subjects and methods
A total of 47 centres in Northern Europe participated in the
CORD study: 14 in Belgium, 13 in the Netherlands, 6 in
Sweden, 5 in Denmark, 5 in Finland and 4 in Norway. Each
site collected information on age, gender, duration of dial-
ysis, diabetic status and smoking (non-smoker, current or
pastsmoker)ofallpatientsonhaemodialysisandperitoneal
dialysis. These data served as a basis for an automated se-
lection procedure that was used to ensure that the CORD
population would be a representative sample of the over-
all dialysis population. A minimum of 20% of the dialysis
patientsineachcentrewasenteredintothestudy.Theinclu-
sion criteria were patient providing informed consent, age
≥18 years and duration of dialysis ≥3 months. Exclusion
criteria were significant co-morbidities that were estimated
to reduce life expectancy to <6 months and patients in
whom it was impossible to measure parameters of arterial
stiffness (e.g. diminished/absent pulses, atrial fibrillation
and bilateral arteriovenous fistulas).
A total of 2102 patients were selected from the database
to participate, and of these, 1009 did not enter the study
based on the eligibility criteria outlined above. Of the
remaining 1093 patients, a lateral lumbar radiograph of
933 patients was available and these formed the basis of the
present study population.
The following baseline biochemical data were obtained
using local routine laboratory methods at the start of the
study: serum calcium, phosphorus, intact parathyroid hor-
mone, albumin, C-reactive protein, total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein
cholesterol and triglycerides. The recorded cardiovascular
history included coronary events (myocardial infarction,
angina pectoris, unstable angina, coronary artery bypass
surgery, percutaneous coronary angioplasty and congestive
heart failure); cerebrovascular events (stroke and transient
ischaemic attacks) and peripheral vascular disease (inter-
mittent claudication, abdominal aortic aneurysm, angio-
plasty, vascular surgery and amputation). Data on weight,
height, body mass index and type and duration of dialy-
sis were obtained as well as use of following medications:
phosphate binders (use and doses of binders containing
calcium, aluminium and/or sevelamer hydrochloride), vita-
min D, oral anticoagulants, statins, angiotensin-converting
enzyme inhibitors/angiotensin II receptor-blocking agents,
beta-blockers, calcium-channel blockers and erythropoi-
etin. Blood pressure was measured in the sitting position
before haemodialysis or during peritoneal dialysis.
Lateral lumbar radiography of aorta
Lateral radiography was performed in the standing posi-
tionusingstandardradiographicequipment.Aminimumof
4 cm anterior to the lumbar spines had to be visible: the
film distance was 100 cm, other adjustments were: 94 KPV,
33-200 mAs and the estimated dose of radiation was ap-
proximately 15 mGy.
Calcification of the aorta was graded using a previously
validated system [10,11] in which both the location and the
severity of calcific deposits at each lumbar vertebral seg-
ment(L1–L4)wereevaluated.Thescoresweresummarized
using two methods: (a) the composite score for anterior–
posterior severity (assigned here as the AAC) where the
scores of individual aortic segments both for the anterior
and posterior walls were summed (maximum score 24),
and (b) the affected segments score as the total number of
aortic segments showing any level of calcification is indi-
cated (maximum score 4). The scoring system is depicted
schematically in Figure 1.
Lateral lumbar radiographs were analysed centrally by
tworeaderswhowereunawareoftheclinicalbackgroundof
thepatients.Doublereadingswereperformedinasubgroup
of 64 patients demonstrating an excellent inter-observer
agreement (intra-class coefficient of correlation 0.9).
Ethical considerations
The study design was approved by local ethics committees,
and patients gave written informed consent before entering
the study.
Statistical analysis
Summary statistics are reported as means ± SE (with
range,and95%confidenceintervalswhereappropriate)for
quantitative variables and as frequencies or percentages
for categorical variables. The unpaired t-test, Mann–
Whitney U-test, one-way analysis of variance (ANOVA)
and Kruskal–Wallis tests were used for analysis between
groups where appropriate. Differences in frequency were
tested using χ2 analysis.Abdominal aortic calcification and dialysis patients 4011
Fig. 1. Abdominal aorta calcification (AAC) scoring. Grading of calcification was assessed at the anterior and the posterior walls of the abdominal
aorta adjacent to vertebrae L1–L4 and the composite score determined.
The independent predictive value of the following base-
line parameters on the AAC score (equal to 0 or ≥1) were
analysed using linear regression analysis with backward
elimination: age (years), gender, diabetic status (yes/no),
duration of dialysis (years), dialysis modality (haemodialy-
sis/peritoneal dialysis), pulse pressure (mmHg), serum cal-
cium(mmol/l),calcium×phosphorousproduct(mmol2/l2)
and the presence or absence of cardiovascular history. The
model quality was evaluated using analysis of residual de-
viance. The odds ratios and their 95% confidence intervals
were also reported. SAS version 8.02 statistical software
package (SAS Institute, Cary, NC, USA) was used for all
statistical analyses.
Results
Patient characteristics
Baseline demographics and laboratory values of the study
population are shown in Tables 1 and 2 and current med-
ications used are listed in Table 3. One patient with the
low serum calcium level of 1.5 mmol/l had a period of
hypocalcaemia at baseline.
Segmental ACC scores
The number of individual aortic segments affected by any
calcific deposit is depicted in Figure 2. In 51% of the pa-
tients, all four segments showed deposits (score > 0), and
between one and three segments were affected in 30% of
patients. Interestingly, 19% of patients had no visible de-
posits (score = 0) in any segment. In 81% of patients who
had an AAC score ≥1, the localization of calcific deposits
was analysed for the individual segments (L1–L4): 54% of
patients had calcifications at level L1, 67% at L2, 75% at
Table 1. Baseline patient characteristics
Characteristic Value
Mean (range) age (years) 61.4 (19–89)
Gender (%)
Male 60.8
Female 39.2
Mean (range) mass index (kg/m2) 25.1 (15.4–46.4)
Diabetes (%)
With 22.9
Without 77.1
Tobacco use (%)
Yes 18.5
No 81.5
History of cardiovascular disease (%)
Yes 43.7
No 56.3
Type of dialysis (%)
Haemodialysis 83.9
Peritoneal dialysis 16.1
Mean (range) duration of dialysis (months) 38.2 (3–363)
Table 2. Blood pressure and laboratory values
Parameter Mean (range)
Systolic blood pressure (mmHg) 146 (72–218)
Diastolic blood pressure (mmHg) 79 (30–141)
Pulse pressure (mmHg) 67 (17–131)
Serum calcium (mmol/l) 2.4 (1.5–3.0)
Serum phosphorus (mmol/l) 1.7 (0.4–3.4)
Calcium phosphorus product (mmol2/l2) 4.0 (0.9–8.3)
S-PTH int (ng/l) 281 (1.0–2505)
Serum C-reactive protein (mg/l) 11 (0–253)
Total serum cholesterol (mmol/l) 4.2 (1.7–9.0)
Serum LDL cholesterol (mmol/l) 2.2 (0.01–6.4)
Serum HDL cholesterol (mmol/l) 1.3 (0.5–3.7)
Serum triglycerides (mmol/l) 1.8 (0.4–17.0)
S-PTH int = intact parathyroid hormone, LDL = low-density lipoprotein,
HDL = high-density lipoprotein.4012 E. Honkanen et al.
Table 3. Current medication of the study population
Agent Percentage
of patients
Mean (range) dose (mg)
Phosphate binders
Calcium containing 73 2026 (200–10 000)
Aluminium containing 4 1734 (400–6000)
Sevelamer 48 4866 (800–16 000)
Vitamin D analogues 52
Oral anticoagulants 14
Statins 35
Angiotensin-converting
enzyme inhibitors or
angiotensin II receptor
blocking agents
39
Beta blocking agents 48
Calcium channel blocking
agents
27
Erythropoiesis stimulating
agents
93
Fig. 2. Number of aortic segments affected by calcific deposits.
L3 and 76% at L4, indicating that calcification developed
in a distal to proximal direction.
The proportion of patients with minimal or no calcifica-
tion, defined as number of affected segments equal to 0 or
1, decreased with age: 54% of the patients <50 years, 27%
ofpatientsaged51–60yearsand<10%inthose>60years
(in whom typically all segments L1–L4 were affected). Ac-
cordingly, age correlated with the number of affected aortic
segments (r = 0.59; P < 0.0001). Patients in whom all
four aortic segments were affected had been on dialysis for
a longer period of time compared to those in whom only
0–2 segments were affected (40 ± 2 months versus 33 ± 2
months, respectively; P = 0.006).
ACC scores
The mean (±SE) AAC score of the study population was
10.3 ± 0.3. No significant gender differences were ob-
served; the mean scores for men and women were 10.2 ±
0.3 and 10.4 ± 0.4, respectively. At a mean age of 61 years,
81% of the CORD patients had calcific deposits in the ab-
dominal aorta (score ≥1). The AAC scores of individual
aortic segments of the CORD population (Figure 3) in-
creased stepwise from 1.6 ± 0.1 at level L1 up to 3.4 ± 0.1
at level L4 (P < 0.0001; ANOVA).
Fig. 3. Abdominal aortic calcification (AAC) scores in segments L1–L4
(n = 933; P < 0.0001).
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Fig.4. Abdominalaorticcalcification(AAC)scoresinindividualpatients
in relation to their age.
Factors associated with ACC scores
There was no significant relationship between AAC and
smoking status, systolic or diastolic blood pressure, phos-
phorus, lipids or CRP (simple regression analysis). The
relationship between age and AAC scores of individual pa-
tients is shown in Figure 4. Overall, calcification scores
increased rapidly with age (r = 0.51, P < 0.0001). Al-
though 31% (70 of 226) patients at the age of ≥50 years
had severe calcification (AAC score > 4), 11% (37 of 336)
patients at the age of ≥70 years had little or no calcifica-
tion (AAC score ≤4) (Figure 5). Patients with a history of
cardiovascular disease had higher AAC scores than those
without(13.9±0.4versus7.9±0.4;P<0.0001).Multiple
logisticregressionanalysiswasusedtoinvestigateindepen-
dent predictors of the presence of calcification (AAC score
>1). The following factors were excluded by the backward
elimination: gender (P = 0.3), diabetic status (P = 0.4),
pulse pressure (P = 0.2), dialysis modality (P = 0.2), base-
line serum calcium (P = 0.7) and calcium × phosphorus
product(P=0.1).IndependentpredictorsofAACincluded
in the final model were age (per 1 year increase; odds ratio
[OR] 1.103; 95% confidence interval [CI] 1.082–1.116;
P < 0.0001), duration of dialysis (per 1 year increase;
OR 1.110; CI 1.040–1.191; P = 0.002) and positive his-
tory of cardiovascular disease (OR 3.247; CI 1.976–5.319;
P < 0.0001).Abdominal aortic calcification and dialysis patients 4013
Fig. 5. Plain X-ray of (A) a 59-year-old patient with abundant abdominal
aortic calcification (AAC = 21) and (B) a 73-year-old patient with no
calcific deposits in the abdominal aorta (AAC = 0).
Discussion
The present multicentre, cross-sectional study comprised
933 patients with dialysis-dependent CKD. AAC was in-
vestigated usingplainlateralradiographs, whicharewidely
available, easy to use, relatively inexpensive and involve
low exposure to radiation. To our knowledge, this is the
largest radiological documentation of arterial calcification
in dialysis patients. The main findings were severe prema-
ture calcification of the abdominal aorta that was related
to age, duration of dialysis and history of cardiovascu-
lar disease. Aortic calcification was most severe in front
of the fourth lumbar segment and decreased towards the
higher lumbar levels. Only one in five patients had no vis-
ible calcification in the abdominal aorta, whereas >50%
had calcification in all four segments, indicating severe
calcification.
Several radiological methods, such as EBCT, multislice
spiral CT and plain radiographs, have been used to inves-
tigate aortic calcification [16,17]. Such methods are costly
and are primarily used for clinical research purposes in
nephrology. A few studies have systematically investigated
plain radiographs as a means of assessing calcification
in dialysis patients [18,19]. None of these methods have
been accepted as a gold standard in cardiovascular risk
assessment (reviewed in [20]). The current study investi-
gated X-rays of the abdominal aorta. In Belgium and the
Netherlands, a special goal was to include up to 50% of
peripheral hospitals. Without the more specific equipment
available in university centres, a simple lateral lumbar X-
ray affords them an easy inexpensive method for the initial
screening of cardiovascular risk in their patients. The scor-
ing system applied is a validated method developed on the
basisoflaterallumbarX-raysfromthegeneralpopulationin
the Framingham heart study [10], where it was proven to be
predictive for cardiovascular riskand outcome [11,12]. The
baseline prevalence of calcification in that cohort, which
had a mean age of 54 years, was 37% in men and 27% in
women and increased significantly during the 25 years of
follow-up. Kiel et al. [21] investigated 554 subjects using
the same methodology and observed that, over a period of
25 years, AAC increased sixfold in men and eightfold in
women in whom the change correlated to the degree of
bone loss.
Several studies suggest that aortic calcification corre-
lates with the findings in coronary arteries, which in turn
predict all-cause mortality [5,13]. In line with these studies
are the findings that the severity of AAC is also an impor-
tant indicator of cardiovascular disease and mortality. Cal-
cification scored using the same system as in the present
study was strongly related to the development of conges-
tiveheartfailure,coronaryheartdiseaseandcardiovascular
events in the general population [11,12]. AAC remained as
an independent predictor of risk even after the adjustment
for traditional cardiovascular risk factors such as diabetes,
olderage,malegender,familyhistoryofcoronaryheartdis-
ease, systolic blood pressure, left ventricular hypertrophy,
smoking, dyslipidaemia and body mass index [11]. In the
present study, a history of cardiovascular events was asso-
ciated with 224% increased odds of calcification. Interest-
ingly, Okuno and co-workers reported recently on a cohort
of 515 haemodialysis patients showing that the presence
of AAC was significantly associated with both all-cause
and cardiovascular mortality during a mean follow-up of
51 months [14].
There was a significant age-related increase in AAC in
the present study, a finding that has previously been shown
in both non-renal [10,22] and renal [23] patients. In the
general population, calcific deposits in the posterior aortic
wall have been shown to occur most commonly at the level
of L4 and in the anterior wall at levels L3 and L4 [24]. In
the present study of ESRD patients, the most pronounced
calcification was also detected at level L4, suggesting that
the distribution of AAC is similar, but more extensive and
premature in ESRD.
Although some reports on the general population [22]
have suggested that men are particularly prone to calcifica-
tion, no significant sex-related difference was observed in
the present study. The duration of dialysis correlates with
calcification in the coronary [23], carotid and peripheral
arteries [8], but the association is less clear in the thoracic
aorta [23]. In the present study, there was a significant
relation between dialysis vintage and AAC: each year on
dialysis increased the odds for AAC ≥1 by 11%. How-
ever, pulse pressure did not predict AAC scores, which is in
line with the recent study by Bellasi and co-workers [13],
wherenoassociationwasfoundbetweenpulsepressureand
coronary artery calcification.
In the CORD study, 19% of patients had no visible cal-
cification in their abdominal aorta, even though some of
them were >80 years of age. These findings are in line
with certain previous observations [2,22], and it has been
suggested that these individuals rarely develop calcifica-
tion at follow-up [2,25,26]. However, in a recent longitu-
dinal study, Asmus et al. [27] followed 72 haemodialysis
patients, of whom 41 used calcium-containing phosphate
binders and 31 used sevelamer hydrochloride. A subset of4014 E. Honkanen et al.
these patients (15%) had no coronary or thoracic aortic cal-
cification at baseline, but their calcification developed dur-
ing 2 years of observation and was most prevalent in those
receiving calcium-containing binders. Thus, it remains to
be proven if the ‘non-calcified’ patients have some typical
biochemical and/or genetic features that protect them from
calcification. The analysis of the aortic X-rays at the 24-
month follow-up of the CORD study will provide further
insight into this question.
The present cross-sectional study has some limitations.
The increased vascular calcification and its relationship
to age and dialysis vintage are well known. In a recent
study [13] on 140 prevalent haemodialysis patients with
a mean age of 55 years and dialysis vintage of 2.7 years,
the mean AAC was 4.4, i.e. much lower than that in the
present study on North European patients. Importantly, pa-
tients with severely reduced life expectancy were excluded.
Furthermore,onlythosepatientsinwhomparametersofar-
terial stiffness by applanation tonometry could be recorded
were included; this measure was impossible in some pa-
tients with severe vascular disease and/or atrial fibrillation.
Most likely this resulted in a favourable selection bias and
the actual calcification burden of dialysis patients may be
even more profound.
In conclusion, severe calcification of the abdominal
aorta as detected by lateral lumbar radiography was found
in this large cohort of dialysis patients from Northern
Europe. The pattern of distribution was similar to previ-
ously reported findings in the general population in the
Framingham heart study, with the most severe lesions de-
tected at the L4 level decreasing towards L1. Importantly,
a subset (19%) of dialysis patients had no evidence of cal-
cification whereas the majority had extensive calcification
involving the entire length of the abdominal aorta. Since
AAC correlates with calcification at other sites (e.g. coro-
nary arteries) and has been shown to have significant prog-
nostic significance for cardiovascular events and mortality,
this easy and inexpensive method may prove to be a use-
ful alternative for CT-based techniques in epidemiological
studiesinpatientswithCKD.Furthermore,itmayserveasa
part of the cardiovascular risk assessment and as a guide to
more sophisticated examinations as recently recommended
by an international expert group [28]. The ongoing CORD
study will provide valuable information about the relation-
ships between AAC, arterial compliance, their evolution
during dialysis or after transplantation and their prognostic
significance.
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